FY 24-25 performance

Share of revenue from India market
0 %
Compounded annual revenue growth over 3 years
0 %
Return on Capital Employed
%
FY25 Revenue from operations
₹ 0 Cr
Earnings per share
₹
Compound annual total return to shareholders over the last 5 fiscal years
0 %
Total FY24 revenues, an increase of 2% in local currency
$ 0 B
FY24 adjusted EPS, a 2% increase over FY23 adjusted EPS; $11.44 FY24 GAAP EPS, a 6% increase.
$ 0
Compound annual total return to shareholders over the last 5 fiscal years
$ 0 B
FY24 cash returned to shareholders
$ 0 B
FY24 adjusted EPS, a 2% increase over FY23 adjusted EPS; $11.44 FY24 GAAP EPS, a 6% increase.
$ 0

Driving Sustainable Growth and Innovation

Emcure is committed to creating long-term value through innovation, operational excellence, and a steadfast focus on delivering impactful healthcare solutions. Guided by a strong foundation of integrity and performance, we strive to achieve sustainable growth while addressing critical medical needs globally.

Track all markets on TradingView

Annual Report FY 2024-25

Click here

Disclosure under Regulation 14 of SEBI (SBEB) Regulations for FY 2024-25

Click here

Annual Report FY 2023-24

Click here

Annual Report FY 2022-23

Click here

Annual Report FY 2021-22

Click here

Subsidaries FS FY 2024-25

Click here

Gennova Biopharmaceuticals Limited Financials March 2024

Click here

Zuventus Healthcare Limited Financials March 2024

Click here

Emcure UK INR Converted Financials FY 2024

Click here

Marcan INR Converted Financials FY 2024

Click here

Tillomed UK INR Converted Financials FY 2024

Click here

Gennova Biopharmaceuticals Ltd. – Financial Statement 2023

Click here

Gennova Biopharmaceuticals Ltd. – Financial Statement 2022

Click here

Gennova Biopharmaceuticals Ltd. – Financial Statement 2021

Click here

Zuventus Healthcare Ltd – Financial Statement 2023

Click here

Zuventus Healthcare Ltd – Financial Statement 2022

Click here

Zuventus Healthcare Ltd – Financial Statement 2021

Click here

Emcure UK INR Converted Financial

Click here

Tillomed UK INR Converted Financial

Click here

Marcan INR Converted Financial

Click here

Subsidaries FS FY 2024-25

Click here

Gennova Biopharmaceuticals Limited Financials March 2024

Click here

Zuventus Healthcare Limited Financials March 2024

Click here

Emcure UK INR Converted Financials FY 2024

Click here

Marcan INR Converted Financials FY 2024

Click here

Tillomed UK INR Converted Financials FY 2024

Click here

Gennova Biopharmaceuticals Ltd. – Financial Statement 2023

Click here

Gennova Biopharmaceuticals Ltd. – Financial Statement 2022

Click here

Gennova Biopharmaceuticals Ltd. – Financial Statement 2021

Click here

Zuventus Healthcare Ltd – Financial Statement 2023

Click here

Voting Results of 44th Annual General Meeting along with Scrutinizer’s Report – 28th August 2024

Click here

Proceedings of 44th Annual General Meeting – 28th August 2025

Click here

Intimation of dispatch of letters to Shareholders whose e-mail addresses are not registered with the Company/Depository Participants

Click here

Intimation of 44th AGM and Annual Report FY 2024-25

Click here

Notice of 44th Annual General Meeting – 28th August 2025

Click here

Intimation of 44th AGM and Record date for Final Dividend

Click here

Proceedings of Postal Ballot – December 2024

Click here

Voting Results of Postal Ballot along with Scrutinizer’s Report – December 2024​

Click here

Notice of Postal Ballot – 7th November 2024

Click here

Notice of 43rd Annual General Meeting – 5th June 2024

Click here

Newspaper Publication of Unaudited Financial Results – Q1 FY26

Click here

Newspaper Publication of Notice of 44th Annual General Meeting – 28th August 2025

Click here

Newspaper Publication of Unaudited Financial Results – Q4 FY25

Click here

Newspaper Publication of Unaudited Financial Results – Q3 FY25

Click here

Newspaper Publication of Postal Ballot Notice – 7th November 2024

Click here

Newspaper Publication of Unaudited Financial Results – Q2 FY25

Click here

Newspaper Publication of Unaudited Financial Results – Q1 FY25

Click here

Credit Ratings

Click here

Credit Ratings

Rating Agency
Instrument Type
Rating

CRISIL Ratings Limited

Long Term Rating

CRISIL AA-/Positive (Upgraded from ‘CRISIL AA-/ Stable’)

Short Term Rating

CRISIL A1+ (Re-affirmed at CRISIL A1+)

CARE Ratings Limited

Long-term bank facilities

CARE AA; Stable (upgraded from CARE AA-; Stable)

Long-term / Short-term bank facilities

CARE AA; Stable / CARE A1+ (Long-term rating upgraded from CARE AA-; Stable and Short-term rating reaffirmed)

Short-term bank facilities

CARE A1+ (Reaffirmed)

Annual Secretarial Compliance Report FY 2024-25

Click here

Annual Return 2024

Click here

Annual Return 2025

Click here

Quarterly Results

Q1

Quarterly Results
Board Meeting Intimation
Earnings Call Invite
Earnings Call Recording
Earnings Call Transcript

Q4

Quarterly Results
Board Meeting Intimation
Earnings Call Invite
Earnings Call Recording
Earnings Call Transcript

Q3

Quarterly Results
Board Meeting Intimation
Earnings Call Invite
Earnings Call Recording
Earnings Call Transcript

Q2

Quarterly Results
Board Meeting Intimation
Earnings Call Invite
Earnings Call Recording
Earnings Call Transcript

Q1

Quarterly Results
Board Meeting Intimation
Earnings Call Invite
Earnings Call Recording
Earnings Call Transcript

Details of Business

Click here

Brief profile of Board of Directors

Click here

Committees of the Board

Click here

Emcure – Memorandum and Articles of Association

Click here

Code of Conduct for Directors and Senior Management

Click here

Vigil Mechanism Policy

Click here

CSR Policy and Composition of CSR Committee

Click here

Nomination and Remuneration Policy

Click here

Archival Policy

Click here

Dividend Distribution Policy

Click here

Policy for Preservation of Documents

Click here

Policy for Determining Material Subsidiaries

Click here

Terms and Conditions of Appointment of Independent Director

Click here

Familiarisation Program for Independent Directors

Click here

Details of Familiarization Programme Imparted to Independent Directors

Click here

Policy for Determining Materiality of Events and Information for Disclosures

Click here

Related Party Transactions Policy

Click here

Code for Prohibition of Insider Trading – w.e.f. June 10, 2025

Click here

Emcure – Employee Stock Option Scheme 2013

Click here

Shareholding Pattern

Click here

Disclosures under Regulation 30

Click here

Disclosures under Regulation 32

Click here

Corporate Governance Filings

Click here

Board Meeting Intimation

Click here

Financial Results

Click here

Financial Results published in Newspaper

Click here

Notices to Shareholders

Click here

Annual Report

Click here

Annual Returns

Click here

Annual Secretarial Compliance Report

Click here

Credit Ratings

Click here

Financial Statement of Subsidiary Companies

Click here

Schedule of analysts or institutional investors meet

Click here

Presentations made by the Company to analysts or institutional investors

Click here

Audio or video recordings and transcripts of post earnings/quarterly calls

Click here

Intimation under Regulation 30(5) – Details of KMPs

Click here

Email address for grievance redressal and other relevant details

Click here

Draft Red Herring Prospectus – 16th December, 2023

Click here

Addendum to Draft Red Herring Prospectus – 18.03.2024

Click here

Red Herring Prospectus – 26th June, 2024

Click here

Prospectus – 5th July, 2024

Click here

Loading...

Intimation under Regulation 30 – Revision in Credit Ratings – CRISIL – 17.10.2025

Click here

US FDA inspection at the manufacturing facility located at Kadu, Surendranagar, Gujarat, India – 10.10.2025

Click here

Intimation under Regulation 30 – Revision in Credit Ratings – CARE – 08.10.2025

Click here

Intimation under Regulation 31A of the SEBI Listing Regulations – Update related to withdrawal of re-classification application

Click here

Intimation under Regulation 30 – Update on completion of acquisition of Equity Shares of Zuventus Healthcare Limited, Subsidiary 03.10.2025

Click here

Allotment of Equity Shares pursuant to exercise of ESOP under Emcure Employee Stock Option Scheme 2013 – 29.09.2025

Click here

Update on re-appointment of Dr. Mukund Gurjar as a Whole-time Director of the Company and appointment of Secretarial Auditor of the Company in the 44th AGM

Click here

Intimation of dispatch of letters to Shareholders whose e-mail addresses are not registered with the Company/Depository Participants

Click here

Audio recording of Earnings call – Q1 FY 26

Click here

Outcome of Board Meeting & Financial Results Q1 FY26

Click here

Appointment of Senior Management Personnel – Mr. R. S. Vasan

Click here

US FDA inspection at the manufacturing facility (Oncology) located at Sanand, Ahmedabad, Gujarat, India – 09.07.2025

Click here

Intimation under Regulation 30 – Incorporation of wholly-owned Subsidiary – Emcure Wellness Private Limited 04.07.2025

Click here

Intimation under Regulation 31A of the SEBI Listing Regulations – Submission of application for seeking re-classification from the ‘Promoter and Promoter Group’ category to ‘Public’ category

Click here

Intimation under Regulation 30 – Regulatory Order received on 24.06.2025

Click here

Intimation under Regulation 31A of the SEBI Listing Regulations – Outcome of the meeting of the Board of Directors considering requests for re-classification from the ‘Promoter and Promoter Group’ category to ‘Public’ category

Click here

Intimation under Regulation 30 – Proposed Incorporation of wholly-owned Subsidiary – Emcure Wellness Private Limited 21.06.2025

Click here

Intimation under Regulation 30 – Acquisition of Equity Shares of Zuventus Healthcare Limited, Subsidiary 21.06.2025

Click here

Outcome of Board Meeting held on 21.06.2025

Click here

Intimation under Regulation 31A – Receipt of requests of re-classification from the ‘Promoter and Promoter Group’ category to ‘Public’ category 19.06.2025

Click here

Intimation under Regulation 30 – Incorporation of wholly-owned Subsidiary – Emcure Lifesciences Private Limited 17.06.2025.

Click here

Allotment of Equity Shares pursuant to exercise of ESOP under Emcure Employee Stock Option Scheme 2013 – 12.06.2025

Click here

Resignation of Senior Management Personnel – Mr. Kothiyal

Click here

Intimation under Regulation 30 – Acquisition Gujarat

Click here

Audio recording of Earnings call – Q4 FY 25

Click here

Re-appointment of Dr. Mukund Gurjar as a Whole-time Director of the Company

Click here

Appointment of Secretarial Auditor of the Company for five years

Click here

Proposed Incorporation of Wholly-owned Subsidiary – 22.05.2025

Click here

Outcome of Board Meeting & Financial Results Q4 FY25

Click here

Update on USFDA inspection at API manufacturing facility located at Kurkumbh, Pune, Maharashtra, India – 18.04.2025

Click here

Allotment of Equity Shares pursuant to exercise of ESOP under Emcure Employee Stock Option Scheme 2013 – 24.03.2025

Click here

US FDA inspection at API manufacturing facility located at Kurkumbh, Pune, Maharashtra, India – 26.02.2025

Click here

Order received on 06.02.2025 by Emcure’s subsidiary

Click here

Audio recording of Earnings Call – Q3 FY25

Click here

Outcome of Board Meeting & Financial Results Q3 FY25

Click here

Orders received on 05.02.2025 by Emcure

Click here

Orders received on 05.02.2025 by Emcure and Subsidiary

Click here

Proceedings of Postal Ballot – December 2024

Click here

Resignation of Senior Management Personnel

Click here

Resignation of Mr. Samonnoi Banerjee, Non-Executive and Non-Independent Director from the Board w.e.f. 23.11.2024

Click here

Allotment of Equity Shares pursuant to exercise of ESOPs under the Emcure- Employee Stock Option Scheme 2013 22.11.2024

Click here

Audio recording of Earnings Call – Q2 FY25

Click here

Outcome of Board Meeting & Financial Results Q2 FY25

Click here

Intimation under Regulation 30 – Incorporation of wholly-owned Subsidiary – Emcutix Biopharmaceuticals Limited 03.10.2024

Click here

Intimation under Regulation 30 – Proposed Incorporation of Wholly-owned Subsidiary 13.09.2024

Click here

Audio recording of Earnings Call – Q1 FY25

Click here

Outcome of Board Meeting & Financial Results Q1 FY25

Click here

Intimation under Regulation 30 – Revision in Credit Ratings – CRISIL – 13.08.2024

Click here

Intimation under Regulation 30 – Revision in Credit Ratings – CARE – 13.08.2024

Click here

Intimation under Regulation 30(5) – Details of KMPs

Click here

Statement of Deviation or Variation Q2 FY25

Click here

Monitoring Agency Report Q2 FY25

Click here

Loading...

Intimation of change in email address of Registrar and Share Transfer Agent of the Company

Click here

Intimation of closure of Trading Window – Q2 FY26

Click here

Intimation of closure of Trading Window – Q1 FY26

Click here

Disclosure of KPIs under the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018

Click here

Intimation of change in email and website address of Registrar and Share Transfer Agent of the Company

Click here

Intimation of closure of Trading Window – Q4 FY25

Click here

Intimation of change in name of Registrar and Share Transfer Agent of the Company

Click here

Intimation of closure of Trading Window – Q3 FY25

Click here

Intimation of closure of Trading Window – Q2 FY25

Click here

Intimation of closure of Trading Window

Click here

Request for Registering PAN, Mobile Number, E-mail address, other KYC details or changes/updation thereof (Form ISR-1)

Click here

Updation of signature of Shareholder (Form ISR-2)

Click here

Declaration Form for opting-out of Nomination by holders of physical securities (Form ISR-3)

Click here

Request for issue of duplicate certificate and other services (Form ISR-4)

Click here

Nomination Form (Form SH-13)

Click here

Cancellation or Variation of Nomination (Form SH-14)

Click here

SEBI/HO/MIRSD/MIRSD-PoD-1/P/CIR/2023/37 – March 16, 2023

Click here

SEBI/HO/MIRSD/POD-1/P/CIR/2023/181 – November 17, 2023

Click here

Loading...

Form No. 10F

Click here

Form No. 15G

Click here

Form No. 15H

Click here

Beneficial Ownership Declaration

Click here

Information under Rule 37bc of Income Tax Rules 1962

Click here

Self Declaration Form

Click here

SEBI
In case the Complaint/grievance stands unresolved/not resolved up to the satisfaction of Investor(s), may lodge a complaint with:

SEBI SCORES Portal: https://scores.gov.in/scores/Welcome.html

Online Dispute Resolution (Smart ODR) Platform: https://smartodr.in/login